CClinicalTrials.gg
CompletedNCT00686192Updated Jul 22, 2008

Calcium and Lipid Metabolism

An interventional study of Calcium Carbonate in Obesity, sponsored by USDA, Western Human Nutrition Research Center. Completed at 1 site in United States. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-07-22.

Sponsored by USDA, Western Human Nutrition Research Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

We hope to determine if supplementing the diet of women who habitually consume low levels of calcium, with 1500 mg of calcium a day for three months will increase fat oxidation and decrease fat storage. We will also measure concentrations of lipids, glucose, hormones and enzymes associated with fat and carbohydrate metabolism to determine alterations and mechanism of the metabolic changes.

Read the detailed description

The incidence of obesity has rapidly increased in recent years and reached epidemic proportions in the United States. Recent epidemiological data has shown an inverse relationship between calcium intake and body fat and emerging research suggests that inadequate dietary calcium consumption may increase obesity. Studies in mice have shown that an increase in dietary calcium consumption creates a shift in the utilization of energy stores from carbohydrates to fat and a shift in the partitioning of energy from storage (as fat) to expenditure (as heat).

We will give 1500 mg of calcium a day for three months to women who habitually consume low levels of dietary calcium. The following measurements will be made before and after calcium supplementation: body fat by DEXA, lipolysis by infusion of stable isotopes of 1,1,2,3,3-[2H5] glycerol , hepatic glucose production by infusion of stable isotopes of 6,6-[2H2] glucose, lipogenesis by measurement of fatty acid synthase activity (14C radiochemical assay) , mRNA expression ( Real Time Polymerase Chain Reaction) and protein content (ELISA), indirect calorimetry measurement of non-protein respiratory quotient (NPRQ), energy expenditure, fat and carbohydrate oxidation. Serum calcium, glucose, cholesterol, triglycerides, LDL, HDL, parathyroid hormone, leptin, free fatty acids, adiponectin, 1,25(OH)2D, 25(OH)D and urinary calcium excretion will also be measured.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Calcium carbonate
  • Dietary Supplements
  • Lipolysis
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 15 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

USDA, Western Human Nutrition Research Center is the lead sponsor of 53 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI between 25 and 30 kg/m2
  • Taking oral contraceptives
  • Having regular menses

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • History of metabolic bone, renal or thyroid disease,
  • History of diabetes mellitus, or gestational diabetes mellitus
  • Cigarette smoking
  • Self-administration of calcium supplements
  • Regular aerobic activity, i.e. jogging > 1 mile/day
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Interventions

  • Dietary supplementCalcium Carbonate

    1500 mg per day

06

What researchers measure

Primary outcomes

  1. Lipolysis by infusion of stable isotopes of 1,1,2,3,3-[2H5] glycerol

    Time frame: 0 and 3 months

Secondary outcomes

  1. Hepatic glucose production by infusion of stable isotopes of 6,6-[2H2] glucose

    Time frame: 0 and 3 months

  2. Lipogenesis by measurement of fatty acid synthase activity (14C radiochemical assay) , mRNA expression ( Real Time Polymerase Chain Reaction) and protein content (ELISA)

    Time frame: 0 and 3 months

  3. Indirect calorimetry measurement of non-protein respiratory quotient (NPRQ), energy expenditure, fat and carbohydrate oxidation

    Time frame: 0 and 3 months

  4. Serum calcium, glucose, cholesterol, triglycerides, LDL, HDL, parathyroid hormone, leptin, free fatty acids, adiponectin, 1,25(OH)2D, 25(OH)D

    Time frame: 0 and 3 months

  5. urinary calcium and sodium excretion

    Time frame: 0 and 3 months

07

Study locations

1 site
  • San Francisco General Hospital
    San Francisco, California 94110, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00686192
Lead sponsor
USDA, Western Human Nutrition Research Center
Collaborators
University of California, Davis, San Francisco General Hospital
First posted
May 29, 2008
Start date
Sep 2001
Primary completion
Jul 2002
Completion
Jul 2002
Last update
Jul 22, 2008

Study contacts

Janet C King, PhD
principal investigator · UCSF Benioff Children's Hospital Oakland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion